共 50 条
- [31] Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab.BLOOD, 2009, 114 (22) : 677 - 677Ahmadi, TahamtanChong, Elise A.Gordon, AmandaAqui, Nicole A.Downs, Lisa H.Leinbach, LeahGoldstein, Steven C.Nasta, Sunita D.Janofsky, StephenManiar, Tapan N.Svoboda, JakubSchuster, Stephen J.
- [32] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trialHAEMATOLOGICA, 2025, 110 (03) : 683 - 692Lin, NingjingSun, XiuhuaZhou, HuiZou, LiqunZhou, KeshuLiu, LihongYang, HaiyanHu, KaiCai, QingqingLiu, YaoJin, JieZhang, LilingLi, WenyuGuo, YeYang, WeiLuo, FengWang, ZhenguangZhu, RongYang, LeiSong, DanSong, YuqinZhu, Jun
- [33] Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trialINTERNATIONAL JOURNAL OF CANCER, 2025,Liu, YanyanLin, NingjingYi, ShuhuaHuang, HuiqiangGuo, YeZhang, QingyuanYang, HaiyanZhang, HuilaiZhang, LilingFeng, RuQian, YijiaoZhu, JiankunSong, YuqinZhu, Jun
- [34] A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin LymphomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (01): : E51 - E60Torka, PallawiPatel, PriyankTan, WeiWilding, GregoryBhat, Seema A.Czuczman, Myron S.Lee, Kelvin P.Deeb, GeorgeNeppalli, VishalaMavis, CoryWallace, PaulHernandez-Ilizaliturri, Francisco J.
- [35] Epstein-Barr virus (EBV) genotypes among human immunodeficiency virus (HIV)-related B-cell Lymphomas and B-cell post-transplant lymphoproliferative disorders (B-PTLD) - late-onset lymphomas, especially in the HIV setting, are associated with type-B-EBVEUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (03) : 227 - 230Ibrahim, Hazem A. H.Menasce, Lia P.Pomplun, SabineBurke, MargaretBower, MarkNaresh, Kikkeri N.
- [36] A RANDOMIZED, OPEN-LABEL, SINGLE-CENTER, PHASE II CLINICAL TRIAL TO EXPLORE THE SAFETY AND EFFICACY OF RECOMBINANT HEPATITIS B IMMUNOGLOBULINTRANSPLANT INTERNATIONAL, 2017, 30 : 231 - 231Song, Gi-WonLee, Sung-GyuHwang, ShinPark, Gil-ChunChung, YongkyuHa, Su-MinKang, Sang-HyunLee, Hyoung UkLee, Yun HeeKwon, Jae-HyunJwa, Eun-KyungCho, Hwui-Dong
- [37] Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM TrialBLOOD, 2016, 128 (22)Witzens-Harig, MathiasViardot, AndreasKeller, UlrichBuske, ChristianCrombe, AnneHoenig, ElisabethAtta, JohannesSchmier, JohannMeissner, JuliaHo, Anthony D.LaRosee, PaulMarks, ReinhardDreyling, MartinHess, Georg
- [38] Results of a phase II multicenter trial of pentostatin and rituximab in patients with low-grade B-cell non-Hodgkin's lymphoma: An effective and minimally toxic regimenCLINICAL LYMPHOMA, 2003, 4 (03): : 169 - 175Drapkin, RDi Bella, NJFaragher, DCHarden, EMatei, CHyman, WMirabel, MBoehm, KAAsmar, L
- [39] Interim results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infectionHEPATOLOGY, 2017, 66 : 20A - 21AWedemeyer, HeinerAlexandrov, AlexanderBogomolov, PavelBlank, AntjeBremer, BirgitVoronkova, NataliaSchoneweis, KatrinRaupach, ReginaLehmann, PatrickDarnedde, MartinaPathil, AnitaBurhenne, JurgenHaag, MathiasSchwab, MatthiasHaefeli, Walter E.Urban, Stephan
- [40] AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II TrialBLOOD, 2020, 136Sasse, StephanieMomotow, JeskoPlutschow, AnnetteHuttmann, AndreasBasara, NadezdaKoenecke, ChristianMartin, SonjaBentz, MartinGrosse-Thie, ChristinaThorspecken, Svende Wit, MaikeKobe, CarstenDietlein, Markusvon Tresckow, BastianFuchs, MichaelBorchmann, PeterEngert, Andreas